How to buy Baudax Bio stock - 22 April
finder.com

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Baudax Bio stock

Own Baudax Bio stock in just a few minutes.

Buy Baudax Bio (BXRX)
Fact checked

Baudax Bio, Inc is a biotechnology business based in the US. Baudax Bio shares (BXRX) are listed on the NASDAQ and all prices are listed in US Dollars. Baudax Bio employs 57 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Baudax Bio

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BXRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

What's in this guide?

  1. BXRX shares summary
  2. Compare share dealing platforms
  3. Is BXRX stock a buy or sell?
  4. Stock performance over time
  5. Can I short BXRX shares?
  6. Baudax Bio's financials
  7. Does Baudax Bio pay a dividend?
  8. Other common questions

Baudax Bio share price

Use our graph to track the performance of BXRX stocks over time.

Baudax Bio shares at a glance

Information last updated 2021-04-15.
52-week range$0.97 - $4.95
50-day moving average $1.32
200-day moving average $1.46
Wall St. target price$4.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.59

Buy Baudax Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Go to site
More Info
Robinhood
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Go to site
More Info
Interactive Brokers
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Go to site
More Info
Webull
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Go to site
More Info
Public
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
Go to site
More Info
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Baudax Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Baudax Bio, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Baudax Bio financials

Revenue TTM $493,000
Gross profit TTM $-1,239,000
Return on assets TTM -55.01%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation $76.1 million

TTM: trailing 12 months

Shorting Baudax Bio shares

There are currently 3.9 million Baudax Bio shares held short by investors – that's known as Baudax Bio's "short interest". This figure is 55.5% up from 2.5 million last month.

There are a few different ways that this level of interest in shorting Baudax Bio shares can be evaluated.

Baudax Bio's "short interest ratio" (SIR)

Baudax Bio's "short interest ratio" (SIR) is the quantity of Baudax Bio shares currently shorted divided by the average quantity of Baudax Bio shares traded daily (recently around 2.7 million). Baudax Bio's SIR currently stands at 1.41. In other words for every 100,000 Baudax Bio shares traded daily on the market, roughly 1410 shares are currently held short.

However Baudax Bio's short interest can also be evaluated against the total number of Baudax Bio shares, or, against the total number of tradable Baudax Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Baudax Bio's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Baudax Bio shares in existence, roughly 60 shares are currently held short) or 0.0565% of the tradable shares (for every 100,000 tradable Baudax Bio shares, roughly 57 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Baudax Bio.

Find out more about how you can short Baudax Bio stock.

Baudax Bio share dividends

We're not expecting Baudax Bio to pay a dividend over the next 12 months.

Baudax Bio overview

Baudax Bio, Inc. , a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; BX2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and BX3000, an NMBA reversal agent, which is under pre-clinical trial, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine, which is under phase II clinical trial. The company was incorporated in 2019 and is based in Malvern, Pennsylvania. .

  1. Technical analysis graphic from TradingView, https://uk.tradingview.com Stock prices and other date from EOD Historical Data

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site